Merck & Company Inc (MRK)vsSerina Therapeutics Inc (SER)
MRK
Merck & Company Inc
$110.95
-1.60%
HEALTHCARE · Cap: $274.03B
SER
Serina Therapeutics Inc
$1.83
-1.08%
HEALTHCARE · Cap: $27.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 50008361% more annual revenue ($65.01B vs $130,000). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SER
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$110.95
$14.47 premium
Margin of Safety
-24.8%
Fair Value
$1.49
Current Price
$1.83
$0.34 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 154.9% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
ROE of -8159.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SER
The strongest argument for SER centers on Revenue Growth. Revenue growth of 154.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SER
The primary concerns for SER are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.82 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while SER is a hypergrowth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
SER is growing revenue faster at 154.9% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 21/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Serina Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Serina Therapeutics Inc is an innovative biotechnology firm dedicated to addressing unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This advanced technology enhances the efficacy of therapies, significantly improving patient outcomes while positioning the company for sustainable growth in the competitive biopharmaceutical landscape. With a robust pipeline of product candidates and strategic collaborations, Serina is poised to transform healthcare solutions, underscoring its commitment to delivering value for investors and advancing therapeutic possibilities.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?